NYSE American - Delayed Quote USD

IGC Pharma, Inc. (IGC)

0.3000
-0.0100
(-3.23%)
At close: June 13 at 4:00:00 PM EDT
0.3035
+0.00
+(1.17%)
After hours: June 13 at 7:58:28 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IGC

Recent News: IGC

View More

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market
ACCESS Newswire 23 days ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
ACCESS Newswire last month
IGC Pharma Welcomes Strategic Investment from Advisors

IGC Pharma Welcomes Strategic Investment from Advisors
ACCESS Newswire last month

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs
ACCESS Newswire last month
IGC Pharma expands CALMA trial with addition of Butler Hospital Program

IGC Pharma expands CALMA trial with addition of Butler Hospital Program
TipRanks 2 months ago
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program
ACCESS Newswire 2 months ago
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
ACCESS Newswire 2 months ago
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
ACCESS Newswire 2 months ago
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
ACCESS Newswire 2 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
ACCESS Newswire 2 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"
ACCESS Newswire 3 months ago
View More

Related Tickers

NKGN NKGen Biotech, Inc.
0.3300
-2.37%
 
OVID Ovid Therapeutics Inc.
0.2802
-3.15%
 
NBY NovaBay Pharmaceuticals, Inc.
0.6000
-6.77%
 
INDP Indaptus Therapeutics, Inc.
0.3248
-4.22%
 
RLYB Rallybio Corporation
0.3240
-1.88%
 
SNSE Sensei Biotherapeutics, Inc.
0.3000
-10.58%
 
MNOV MediciNova, Inc.
1.3300
-3.62%
 
MRSN Mersana Therapeutics, Inc.
0.3672
+1.13%
 
ACXP Acurx Pharmaceuticals, Inc.
0.3050
-7.60%
 
ERNA Ernexa Therapeutics Inc.
2.2900
-3.38%